[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335714-105":59,"doc-detail-335714-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optimizing-t-cell-inflamed-signature-through-a-combination-biomarker-approach-for-predicting-immunotherapy-response-in-nsclc","Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC","","Anti-PD-1/PD-L1 therapies changed treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain limited, driving the need for reliable predictive biomarkers. A T cell inflamed gene expression profile (GEP) failed to predict anti-PD-1 response in a large SU2C-MARK NSCLC cohort. Re-analysis showed the T cell inflamed GEP alone was insufficient, but prediction improved when combined with immune-altered signatures related to myeloid markers. A machine-learning–derived combination was validated across six independent anti-PD-1 cohorts, with enhanced performance in NSCLC and gastric cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optimizing-t-cell-inflamed-signature-through-a-combination-biomarker-approach-for-predicting-immunotherapy-response-in-nsclc/335714/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optimizing-t-cell-inflamed-signature-through-a-combination-biomarker-approach-for-predicting-immunotherapy-response-in-nsclc/335714.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why were anti-PD-1/PD-L1 predictive biomarkers needed for NSCLC?","Question",{"text":112,"@type":113},"Although anti-PD-1/PD-L1 therapies improved outcomes, monotherapy response rates remained modest, so identifying patients likely to benefit required better predictive biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about the T cell inflamed GEP in the SU2C-MARK NSCLC cohort?",{"text":117,"@type":113},"The T cell inflamed GEP alone was not predictive of anti-PD-1 response in the SU2C-MARK NSCLC cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"How did combining biomarkers improve prediction and in which cancers was it effective?",{"text":121,"@type":113},"Combining the T cell inflamed GEP with immune-altered signatures improved predictive performance in NSCLC and gastric cancer cohorts, but not in melanoma cohorts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335714,1790430833,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nOptimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC  \nYun-Ching Chen􀀍, Ariel Yung-Chia Chen, Rui Hong, Bevan Emma Huang & Mehdi Pirooznia􀀍  \nThe introduction of anti-PD-1/PD-L1 therapies revolutionized treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain modest, underscoring the need for predictive biomarkers. While aT cell inflamed gene expression profile (GEP) has predicted anti-PD-1 response in various cancers, it failed in a large NSCLC cohort from the Stand Up To Cancer-Mark (SU2C-MARK) Foundation. Re-analysis revealed that while the T cell inflamed GEP alone was not predictive, its performance improved significantly when combined with gene signatures of myeloid cell markers. These additional signatures, however, showed negative contributions to prediction, hinting at immune alterations affecting therapy. Based on this, we proposed a combination biomarker approach that integrates the T cell inflamed GEP with immune-altered signatures, derived from the SU2CMARK cohort using a machine-learning approach, as novel biomarkers. These signatures consisted of genes highly expressed in myeloid and stromal cells. We then assessed the predictive ability of these combined biomarkers in six independent cancer cohorts treated with anti-PD-1. The combined biomarkers demonstrated enhanced performance in NSCLC and gastric cancer cohorts, but not in melanoma cohorts. Our study introduces new biomarkers for predicting anti-PD-(L)1 response in NSCLC and offers mechanistic insights into treatment efficacy.  \nLung cancer is the leading cause of cancer mortality worldwide1. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with 5-year survival rates of 21–32% for all stages and 6–11% for metastatic disease depending on the subtypes2. The introduction of anti-PD-(L)1 antibodies has made a paradigm shift in treatment of advanced NSCLC. These agents have demonstrated improved overall survival either as monotherapy3–6orin combination with chemotherapy7,8or an anti-CTLA4 therapy9. However, the response rate of monotherapy remains modest, ranging from 20 to 30%10–14. Therefore, the development of predictive biomarkers is crucial to identify the patients likely to benefit from these treatments.  \nTo date, the level of PD-L1 expressed on tumor cell membranes and tumor mutational burden (TMB) have emerged as the primary predictive biomarkers for immunotherapy response in NSCLC15. In addition, several transcriptomic signatures have been published for predicting treatment response. These signatures predominantly focus on genes associated with T cell inflammation and/or IFN-γ signaling16–21, which indicate an inflammatory tumor microenvironment (TME) that favors responsiveness to immunotherapy.  \nAmong these predictive signatures, a T cell inflamed gene expression profile (GEP) consisting of 18 genes was developed based on a cohort of 220 patients across 9 cancer types16. Its predictive performance has been validated in a pan-cancer clinical trial with patients across 20 cancer types21, and has been shown to be independent of TMB in a cohort of over 300 patients across 22 cancer types22. Despite those promising results, the limited representation of lung cancer patients in these pan-cancer cohorts leaves performance of the T cell inflamed GEP in NSCLC still somewhat uncertain.  \nThe first integrative analysis of the Stand Up To Cancer-Mark (SU2C-MARK) Foundation NSCLC cohort was recently published23. This dataset comprises 393 NSCLC patients who received checkpoint inhibitors in the advanced-stage setting. The dataset includes whole-exome sequencing (WES) and RNA sequencing (RNAseq) data, along with detailed clinical outcomes. As a result, it serves as a valuable resource for evaluating and developing molecular biomarkers in NSCLC.  \nThe authors found","cbCaimU8mX8lbNXN","https://ap.wps.com/l/cbCaimU8mX8lbNXN","pdf",5493844,13,"English","# Introduction\n## Predictive biomarkers for anti-PD-(L)1 response\n## T cell inflamed GEP and prior validation\n## SU2C-MARK cohort resource\n## Study objective and approach\n# Results\n## Performance of individual gene signatures\n## Combined biomarker performance across cohorts","[{\"question\":\"Why were anti-PD-1/PD-L1 predictive biomarkers needed for NSCLC?\",\"answer\":\"Although anti-PD-1/PD-L1 therapies improved outcomes, monotherapy response rates remained modest, so identifying patients likely to benefit required better predictive biomarkers.\"},{\"question\":\"What did the study find about the T cell inflamed GEP in the SU2C-MARK NSCLC cohort?\",\"answer\":\"The T cell inflamed GEP alone was not predictive of anti-PD-1 response in the SU2C-MARK NSCLC cohort.\"},{\"question\":\"How did combining biomarkers improve prediction and in which cancers was it effective?\",\"answer\":\"Combining the T cell inflamed GEP with immune-altered signatures improved predictive performance in NSCLC and gastric cancer cohorts, but not in melanoma cohorts.\"}]","Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC | PDF",1790012034,33]